uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
17.99
+3.72 (26.07%)
At close: Mar 9, 2026, 4:00 PM EDT
17.94
-0.05 (-0.28%)
After-hours: Mar 9, 2026, 7:06 PM EDT
uniQure Employees
uniQure had 209 employees as of December 31, 2024. The number of employees decreased by 271 or -56.46% compared to the previous year.
Employees
209
Change (1Y)
-271
Growth (1Y)
-56.46%
Revenue / Employee
$77,024
Profits / Employee
-$952,014
Market Cap
1.12B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| Geron | 229 |
| Inhibrx Biosciences | 161 |
| ORIC Pharmaceuticals | 104 |
| Inventiva | 84 |
| ArriVent BioPharma | 52 |
QURE News
- 10 hours ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 4 days ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 4 days ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 4 days ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters
- 4 days ago - FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Benzinga
- 4 days ago - FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters
- 6 days ago - These Analysts Cut Their Forecasts On uniQure Following Q4 Results - Benzinga
- 6 days ago - uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade) - Seeking Alpha